Cargando…
P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430408/ http://dx.doi.org/10.1097/01.HS9.0000846528.55550.9c |
| _version_ | 1784779760964993024 |
|---|---|
| author | Kastritis, E. Minnema, M. C. Dimopoulos, M. A. Merlini, G. Theodorakakou, F. Fotiou, D. Huart, A. Belhadj, K. Gkolfinopoulos, S. Manousou, K. Sonneveld, P. Palladini, G. |
| author_facet | Kastritis, E. Minnema, M. C. Dimopoulos, M. A. Merlini, G. Theodorakakou, F. Fotiou, D. Huart, A. Belhadj, K. Gkolfinopoulos, S. Manousou, K. Sonneveld, P. Palladini, G. |
| author_sort | Kastritis, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430408 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94304082022-08-31 P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK Kastritis, E. Minnema, M. C. Dimopoulos, M. A. Merlini, G. Theodorakakou, F. Fotiou, D. Huart, A. Belhadj, K. Gkolfinopoulos, S. Manousou, K. Sonneveld, P. Palladini, G. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430408/ http://dx.doi.org/10.1097/01.HS9.0000846528.55550.9c Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Kastritis, E. Minnema, M. C. Dimopoulos, M. A. Merlini, G. Theodorakakou, F. Fotiou, D. Huart, A. Belhadj, K. Gkolfinopoulos, S. Manousou, K. Sonneveld, P. Palladini, G. P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title | P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_full | P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_fullStr | P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_full_unstemmed | P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_short | P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_sort | p915: efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3b light chain amyloidosis: a phase 2 study by the european myeloma network |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430408/ http://dx.doi.org/10.1097/01.HS9.0000846528.55550.9c |
| work_keys_str_mv | AT kastritise p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT minnemamc p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT dimopoulosma p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT merlinig p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT theodorakakouf p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT fotioud p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT huarta p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT belhadjk p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT gkolfinopouloss p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT manousouk p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT sonneveldp p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT palladinig p915efficacyandsafetyofdaratumumabmonotherapyinnewlydiagnosedpatientswithstage3blightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork |